Lynne Dawkins
KAC Communications is proud to be welcoming Professor Lynne Dawkins of the Centre for Addictive Behaviours Research at London South Bank University to GFN19. Professor Dawkins will be exploring whether nicotine has any beneficial effects for users. With over 20 years’ experience of working with smokers and, more recently, electronic cigarette users, Professor Dawkins is one of the UK’s leading authorities on e-cigarettes, having published papers on profiles of use, acute effects, puffing topographies, nicotine delivery and smoking cessation.

Our conference theme is ‘It’s time to talk about nicotine.’ Does your work lead you to believe that nicotine has beneficial effects for those who use it? What about the downsides?

The title of my talk is ‘Beneficial effects of nicotine: fact or fiction’. Following Professor Paul Newhouse’s presentation last year on the treatment of disorders of the aging brain with nicotine, I will be exploring the effects of nicotine on cognition, mood and reward in the healthy population. Whether nicotine has any beneficial or advantageous effects for the non-clinical population is hotly debated. As many of the enhancing effects of nicotine (e.g. mood enhancement, stress reduction, cognitive enhancement) are often related to the reversal of withdrawal in smokers, these effects can be difficult to disentangle. However, newer research on non-smokers and non-dependent smokers can begin to answer this question.

It seems that nicotine is more likely to exacerbate stress and negative mood rather than improve it. However, there is some evidence that nicotine can yield performance enhancements in some areas of attention and memory and possibly enhance the effects of other rewarding activities (e.g. listening to music). Research in this area is complicated by difficulties in separating nicotine from smoking and acute and chronic effects.

You used to work with smokers, and now your research sees you focused on e-cigarette users. Does the work feel significantly different to you? What about the population you are working with?

I am continuing to work with both smokers and e-cigarette users including those who use both products (‘dual users’). Since my work focuses on a range of different methods to help smokers to quit, the work doesn’t feel significantly different. E-cigarettes work very well as a cessation aid for some smokers, but many others have either not tried them or not found them sufficiently satisfying to fully support smoking cessation. Exploring other routes to cessation and understanding the processes and mechanisms underlying success among different populations remain of paramount importance. A key area of my work at present is around supporting homeless smokers to quit (including through the use of e-cigarettes), as smoking prevalence is amongst the highest in this group, who experience multiple disadvantages.

How do you feel the UK is doing with regards to the development of the science around safer nicotine products?

The UK, with its focus on tobacco harm reduction continues to be a leader in nicotine and tobacco research and the key funders (Cancer Research UK and the National Institute of Health Research in particular) are increasing their support for e-cigarette research and working to identify research gaps. Public Health England and the Stoptober campaign have also helped to disseminate findings and present accurate information on reduced risk products, but more could be done nationally and globally to disseminate accurate, evidence-based information.

And finally, who are you hoping to hear speak at GFN19? Why would you recommend people come to GFN19?

The GFN is unique in its approach of allowing and encouraging attendance and dissemination from a variety of academics, policy makers, industry, charities and advocacy groups which brings different perspectives together under one roof. I am looking forward to hearing a diverse range of talks, but especially the session on vulnerable and hard to reach populations, who suffer the worst health-related consequences of smoking.

Register NOW


  • LOCAL
    &
    REDUCED
  • £129
  • This fee applies to Polish delegates, living and/or working in Poland and to private individuals resident and working in middle and low-income countries (please see World Bank classifications for details). It also applies to consumers (eg vapers and snus users) who are not employed by, or representing manufacturers, vendors or trade associations, and to those who are unwaged, including students in full-time education.
  • Sign Up

  • ACADEMIC
    PUBLIC SECTOR
    NGOS
  • £265
  • This fee applies to individuals who are employed in education and/or research in the public sector, public sector organisations and NGOs.
  • ?
  • SIGN UP
  • SMALL
    &
    MEDIUM
    ENTERPRISES
  • £350
  • This fee applies to those employed in, or representing small and medium enterprises (those with 20 or less employees and/or a turnover of less than £1m) producing or trading in nicotine products, providing services to them, or trade associations.
  • Sign UP

  • INDUSTRY
    &
    CONSULTANTS
  • £660
  • This fee applies to those who are employed by, or represent healthcare companies and those producing or trading in nicotine products, as well as to private consultancies and research companies.
  • Sign UP

Organisers

KAC Communications the organiser of GFN is committed to providing a platform for global public health debate, knowledge exchange and networking, underpinned by the principles of inclusiveness and multi-sectoral engagement

Company Details

KAC-Communications
8 Northumberland Avenue
London
WC2N 5BY

+48 501 188 768
gfn@kaccommunications.eu

Tags

  • GFN
  • Tobacco harm reduction
  • Nicotine
  • Global Forum
  • Marriott
  • Michael Russell